Evaluation of adenoma size and cortisol secretion status in patients with adrenal incidentalomas at long-term follow-up
Main Article Content
Abstract
Context Increased prevalence of adrenal incidentalomas (AIN) necessitates clarification of optimal follow-up for benign adrenal adenomas without overt hormone excess.
Aim: To evaluate the radiological and hormonal assessment of AIN patients to determine the risk of malignant transformation, development of overt hormone excess or mild autonomous cortisol secretion (MACS) during long-term follow-up.
Materials and Methods: Retrospective cohort study. In a total number of 908 AIN patients, eligible 467 patients with adrenal adenomas were enrolled.
Results: Median age was 55 (21-85) years with a female dominance (73.4%). Median adenoma size was 20 (10-65) mm. Median follow-up duration was 60 (12-204) months. Increase in adenoma size was observed in 36.8% and significant increase (≥10mm) was observed in 4.7% of the patients. Development of overt hormone secretion or adrenocortical carcinoma was not detected while 13 patients with NFA (3.9% of NFA) transformed to MACS and 3 patients with MACS (10.2% of MACS) transformed to NFA at follow-up. Among 13 patients transformed from NFA to MACS, 39% featured ≥10mm increase in adenoma size while this was 4% in patients with stable cortisol secretion level during follow-up (p<.001). Transforming from NFA to MACS at follow-up was the strongest independent predictor of an increase ≥10mm in size in multivariate analysis [Beta: 2.352, OR(CI%): 10.5- (2.8-39.2), p< .001].
Conclusion: Incidentally discovered adrenal adenomas feature a stable course in terms of adenoma size and hormonal status. However, given our findings demonstrating an interrelation between adenoma enlargement and MACS development, follow-up radiological and hormonal work-up should be individualized.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Ebbehoj A, Li D, Kaur RJ, et al. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol. Nov 2020;8(11):894–902. doi:10.1016/S2213-8587(20)30314-4
3. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. Jun 2011;164(6):851–70. doi:10.1530/EJE-10-1147
4. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. Jul 20 2023;189(1):G1–G42. doi:10.1093/ejendo/lvad066
5. Prete A, Bancos I. Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches. Nat Rev Endocrinol. Aug 2024;20(8): 460–473. doi:10.1038/s41574-024-00984-y
6. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. Oct 2009;161(4):513–27. doi:10.1530/EJE-09-0234
7. Fassnacht M, Puglisi S, Kimpel O, Terzolo M. Adrenocortical carcinoma: a practical guide for clinicians. Lancet Diabetes Endocrinol. May 2025;13(5):438–452. doi:10.1016/S2213-8587 (24)00378-4
8. Anagnostis P, Efstathiadou Z, Polyzos SA, et al. Long term follow-up of patients with adrenal incidentalomas--a single center experience and review of the literature. Exp Clin Endocrinol Diabetes. Oct 2010;118(9):610–6. doi:10.1055/s-0029-1237704
9. Vassilatou E, Vryonidou A, Michalopoulou S, et al. Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf). May 2009;70(5):674–9. doi:10.1111/j.1365-2265.2008.03492.x
10. Yilmaz N, Avsar E, Tazegul G, Sari R, Altunbas H, Balci MK. Clinical Characteristics and Follow-Up Results of Adrenal Incidentaloma. Exp Clin Endocrinol Diabetes. May 2021;129(5):349–356. doi:10.1055/a-1079-4915
11. Bertherat J, Bourdeau I, Bouys L, Chasseloup F, Kamenicky P, Lacroix A. Clinical, Pathophysiologic, Genetic, and Therapeutic Progress in Primary Bilateral Macronodular Adrenal Hyperplasia. Endocr Rev. Jul 11 2023;44(4):567–628. doi:10.1210/endrev/bnac034
12. Araujo-Castro M, Iriarte-Duran MB, Parra-Ramirez P, Donato S. Management of adrenal incidentalomas: who, why and how? Curr Opin Endocrinol Diabetes Obes. May 15 2025; doi:10.1097/MED.0000000000000917
13. Elhassan YS, Alahdab F, Prete A, et al. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med. Jul 16 2019;171(2):107–116. doi:10.7326/M18-3630
14. Iriarte-Duran MB, Donato S, Herrera A, et al. The impact of mild autonomous cortisol secretion and proposed interventions. Expert Rev Endocrinol Metab. Jul 2025;20(4):251–266. doi:10.1080/17446651.2025.2480704
15. Papanastasiou L, Alexandraki KI, Androulakis, II, et al. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up. Clin Endocrinol (Oxf). Apr 2017;86(4):488–498. doi:10.1111/cen.13294
16. Athimulam S. Cardiometabolic risk and therapeutic outcomes in mild autonomous cortisol secretion. Curr Opin Endocrinol Diabetes Obes. Jul 2025; doi: 10.1097/MED.0000000000000922
17. Farah S, Nasr L, Eid Fares J. An Overlooked Disease: Minimal Autonomous Cortisol Secretion (MACS) A Narrative Review. Endocr Metab Immune Disord Drug Targets. Jul 2024;24(13):1518-1524.
18. Tizianel I, Barbot M, Ceccato F. Subtyping of Cushing's Syndrome: A Step Ahead. Exp Clin Endocrinol Diabetes. Dec 2024; 132(12): 659-669.
19. Exp Clin Endocrinol Diabetes et al. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis. Eur J Endocrinol. Oct 2023; 189(4):S88-S101.
20. Park SS, Kim JH. Recent Updates on the Management of Adrenal Incidentalomas. Endocrinol Metab (Seoul). Aug 2023; 38(4):373-380.
21 Yener S, Genc S, Akinci B, et al. Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma. Endocrine. 2009, 35(3):365–370.
22 Yener S, Baris M, Secil M et al. Is there an association between non-functioning adrenal adenoma and endothelial dysfunction? J Endocrinol Invest 2011, 34(4):265–270.
23 Androulakis, II, Kaltsas GA, Kollias GE et al. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab 2014, 99(8):2754–2762.
24 Athanasouli F, Georgiopoulos G, Asonitis N et al. Nonfunctional adrenal adenomas and impaired glucose metabolism: a systematic review and meta-analysis. Endocrine 2021; 74(1):50–60.
25 Lopez D, Luque-Fernandez MA, Steele A et al. "Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study. Ann Intern Med 2016; 165(8):533–542.
26. Araujo-Castro M, Parra Ramirez P, Martin Rojas-Marcos P et al. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 microg/dL have a higher prevalence of cardiovascular disease than those with values